ClinicalTrials.gg
RecruitingNCT07307235Updated Jul 7, 2026

Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents

A Phase 4 interventional study of iGlarLixi (insulin glargine/lixisenatide) and standard of care (basal insulin or premixed insulin, excluding any GLP-1 receptor agonist-containing drugs) in Type 2 Diabetes, sponsored by Shanghai Zhongshan Hospital. Recruiting at 24 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Shanghai Zhongshan Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,316
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Diabetes Mellitus, Type 2 by Shanghai Zhongshan Hospital — 4 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Shanghai Zhongshan Hospital.

Planned enrollment
2nd of 13
1,316 · median 120
Started
2025
with 1 other
Phase 4
6 of 15
2 open now
Registered
14th of 15
by date

Among the 15 studies in Diabetes Mellitus, Type 2 by Shanghai Zhongshan Hospital, this one is the 2nd largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2025, is one of 6 in phase 4, and was the 14th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 15 studies in Diabetes Mellitus, Type 2 by Shanghai Zhongshan Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Diabetes Mellitus, Type 2 by Shanghai Zhongshan Hospital, or all of them as a file.
02

Study summary

This study is a prospective, open-label, multicenter, parallel-group, positive-controlled, and pragmatic randomized clinical trial (pRCT). It will compare the efficacy and safety of iGlarLixi versus standard of care in adult T2DM patients with poor glycemic control, who are using 1 to 3 OADs in a real-world clinical practice setting. A total of 1,316 subjects from approximately 40 research centers in China will be randomly assigned in a 1:1 ratio to one of the following treatment groups: Group 1: iGlarLixi for blood glucose control; and Group 2: Standard of care for diabetes (basal insulin or premixed insulin, excluding any GLP-1RA-containing drugs). Considering the substantial difference in intervention methods between the two groups, the study is designed as non-blinded with an open-label approach.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • diabetes
  • iGlarLixi
  • RCT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be at least 18 of age inclusive, at the time of signing the .
  2. Type 2 diabetes mellitus diagnosis.
  3. Participants who are treated for at least 3 months prior to the screening visit with an adequate dose of 1-3 OADs.
  4. 7.5-11%
  5. Further intensification with an additional antidiabetic injectable medication is indicated to achieve glycaemic target at the discretion of the study physician according to approval labelling.

Participants who have signed informed consent form (ICF).

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed with T1DM
  2. \<20 kg/m2 or BMI ≥40 kg/m2
  3. Treatment with more than 3 oral antidiabetic medications, or any injectable medication in a period of 30 days before the day of eligibility assessment. Temporary/emergency use of insulin is allowed, as is prior insulin treatment for gestational diabetes.
  4. to iGlarLixi according to the China NMPA approved label.
  5. Any abnormality identified on physical examination, laboratory tests, or vital signs at the time of screening, or any major systemic disease resulting in short that in the opinion of the Investigator would restrict or limit the patient's successful participation for the duration of the study.
  6. Participants who involved in other clinical trial within 3 months prior to the time of screening visit.
  7. Participant who has a severe renal function impairment with an estimated (eGFR) \<30 mL/min/1.73m2
  8. Pregnant or breast-feeding woman.
  9. Woman of not protected by highly effective method of birth control and/or who is unwilling or unable to be tested for pregnancy.
  10. Conditions/situations such as:

Participant with short life expectancy. Participant with conditions/concomitant diseases making him/her not evaluable for the primary efficacy endpoint (eg, hemoglobinopathy or hemolytic anemia, receipt of blood or plasma products within 3 months prior to screening).

Participant with conditions/concomitant diseases precluding his/her safe participation in this study (eg, active malignant tumor, major systemic diseases, presence of clinically significant diabetic retinopathy or presence of macular edema likely to require laser treatment within the study period).

Uncooperative or any condition that could make the participant potentially non-compliant to the study procedures.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,316 participants (estimated)

Study arms

  • Experimental
    iGlarLixi group

    The investigational drug is iGlarLixi. Participants will receive subcutaneous injections of iGlarLixi with the OAD treatment regimen being appropriately maintained or adjusted as intensification therapy in routine clinical practice.

    Drug: iGlarLixi (insulin glargine/lixisenatide)

  • Active comparator
    Standard of care (SOC) group.

    The control drug treatment is standard of care (basal insulin or premixed insulin, excluding any GLP-1 receptor agonist-containing drugs). Participants will receive standard of care with the OAD treatment regimen being maintained or appropriately adjusted as an intensification treatment during routine clinical practice.

    Drug: standard of care (basal insulin or premixed insulin, excluding any GLP-1 receptor agonist-containing drugs)

Interventions

  • DrugiGlarLixi (insulin glargine/lixisenatide)

    The investigational drug is iGlarLixi. Participants will receive subcutaneous injections of iGlarLixi with the OAD treatment regimen being appropriately maintained or adjusted as intensification therapy in routine clinical practice.

  • Drugstandard of care (basal insulin or premixed insulin, excluding any GLP-1 receptor agonist-containing drugs)

    The control drug treatment is standard of care (basal insulin or premixed insulin, excluding any GLP-1 receptor agonist-containing drugs). Participants will receive standard of care with the OAD treatment regimen being maintained or appropriately adjusted as an intensification treatment during routine clinical practice.

06

What researchers measure

Primary outcomes

  1. hemoglobin A1c (HbA1c) change

    The primary endpoint is the change in HbA1c from baseline to week 24 (percentage \[%\]).

    Time frame: from baseline to week 24

Secondary outcomes

  1. Proportion of subjects achieving HbA1c < 7% at week 24

    Time frame: 24 weeks

  2. Proportion of subjects achieving HbA1c < 7%, with no weight gain and no hypoglycemia (defined as ADA grades 1, 2, or 3) at week 24

    Time frame: 24 weeks

  3. Change in weight from baseline to week 24

    Time frame: 24 weeks

  4. Change in Fasting plasma glucose from baseline to Week 24.

    Time frame: 24 weeks

  5. Change in 7-point self-monitored plasma glucose (SMPG) profile from baseline to Week 24 (each time point and average daily value).

    Time frame: 24 weeks

  6. Proportion of participants reaching HbA1c target <7% with no hypoglycemia (defined as ADA level 1, 2 or 3) at Week 24.

    Time frame: 24 weeks

  7. Proportion of participants reaching HbA1c target <7% with no clinically relevant hypoglycemia (defined as ADA level 2 or 3) at Week 24

    Time frame: 24 weeks

  8. Change in CGM metrics(TIR / TAR / TBR /mean daily glucose / TITR / CV / GMI / SD of mean glucose) from baseline to Week 24

    Time frame: 24 weeks

  9. Change in proportion of patients achieving CGM metrics targets (TIR / TAR / TBR / TITR / CV) from baseline to Week 24

    Time frame: 24 weeks

  10. Change in waist from baseline to Week 24

    Time frame: 24 weeks

  11. Total insulin dose in each group at Week 24

    Time frame: 24 weeks

  12. Change in fasting C-peptide from baseline to Week 24

    Time frame: 24 weeks

  13. Percentage of participants requiring rescue therapy during the 24-week treatment period

    Time frame: 24 weeks

  14. Time to first study drug discontinuation during 24 weeks (day)

    Time frame: 24 weeks

  15. Time to first treatment intensification (add-on) or change (switch) after randomization during 24 weeks (day)

    Time frame: 24 weeks

  16. Study drug medication adherence of the study, as measured by medication possession ratio (MPR) (%)

    Time frame: 24 weeks

  17. Change from baseline to Week 24 in diabetes medication treatment satisfaction scores (total score and by sub scales), using the treatment related impact measure diabetes (TRIM-D) questionnaire.

    TRIM scores range from 0 to 100 with a higher score indicating a better health state.

    Time frame: 24 weeks

  18. All cause healthcare resource utilization (HCRU) from baseline to EOT(end of treatment

    Time frame: 24 weeks

  19. Incidence and event rate of hypoglycemia

    any hypoglycemia, ADA grades 1-2-3

    Time frame: 24 weeks

  20. Incidence and event rate of Adverse events (AE)

    Time frame: 24 weeks

  21. Incidence and event rate of serious adverse events (SAE)

    An SAE is defined as any adverse event occurring at any dose that meets one or more of the following criteria: 1. Results in death 2. Is life-threatening 3. Requires hospitalization or prolongs existing hospitalization 4. Results in persistent or significant disability/incapacity 5. Is a congenital anomaly/birth defect 6. Other important medical events

    Time frame: 24 weeks

  22. Incidence and event rate of adverse events of special interest (AESI)

    The following events are designated as AESIs: 1. Pregnancy in female subjects or pregnancy in female partners of male subjects exposed to IMP/NIMP 2. Symptomatic overdose of IMP/NIMP (serious or non-serious) 3. Alanine aminotransferase (ALT) elevation \>3×ULN

    Time frame: 24 weeks

  23. Incidence and event rate of AEs leading to treatment discontinuation, vital signs, and safety laboratory test values.

    Time frame: 24 weeks

Other outcomes

  1. Change in CRP from baseline to week 24.

    Change in CRP from baseline to week 24.

    Time frame: from baseline to week 24

07

Study locations

24 of 24 sites recruiting
  • The First Affiliated Hospital of USTC / Anhui Provincial Hospital
    Hefei, Anhui 230001, China
    Recruiting
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230022, China
    Recruiting
  • The First People's Hospital of Huizhou
    Huizhou, Guangdong 516003, China
    Recruiting
  • Shenzhen Third People's Hospital
    Shenzhen, Guangdong 518112, China
    Recruiting
  • Heilongjiang Provincial Hospital
    Harbin, Heilongjiang 150036, China
    Recruiting
  • Xinxiang Central Hospital
    Xinxiang, Henan 453003, China
    Recruiting
  • Wuhan Fourth Hospital / Wuhan Puai Hospital
    Wuhan, Hubei 430030, China
    Recruiting
  • Hunan Provincial People's Hospital / The First Affiliated Hospital of Hunan Normal University
    Changsha, Hunan 410005, China
    Recruiting
  • Hengyang Central Hospital
    Hengyang, Hunan 421001, China
    Recruiting
  • Affiliated Nanhua Hospital, University of South China
    Hengyang, Hunan 421002, China
    Recruiting
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210003, China
    Recruiting
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
    Recruiting
  • The First Clinical Hospital of Jilin Academy of Chinese Medicine Sciences
    Changchun, Jilin 130021, China
    Recruiting
  • Zhongshan Hospital, Fudan University
    Shanghai, Shanghai Municipality 200032, China
    Recruiting
  • Shanghai Tenth People's Hospital / Tenth People's Hospital of Tongji University
    Shanghai, Shanghai Municipality 200072, China
    Recruiting
  • Shanghai East Hospital, Tongji University
    Shanghai, Shanghai Municipality 200120, China
    Recruiting
  • Shanghai Pudong New Area Punan Hospital
    Shanghai, Shanghai Municipality 200125, China
    Recruiting
  • Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality 200336, China
    Recruiting
    • Shan Huang · Contact+86 21 52039999
  • Minhang Hospital, Fudan University / Central Hospital of Minhang District, Shanghai
    Shanghai, Shanghai Municipality 201199, China
    Recruiting
  • Shanghai Qingpu District Central Hospital / Qingpu Branch of Zhongshan Hospital, Fudan University
    Shanghai, Shanghai Municipality 201700, China
    Recruiting
  • Zhejiang Provincial People's Hospital
    Hangzhou, Zhejiang 310014, China
    Recruiting
  • Jiaxing First Hospital
    Jiaxing, Zhejiang 314001, China
    Recruiting
  • Ningbo No. 2 Hospital
    Ningbo, Zhejiang 315010, China
    Recruiting
  • Ningbo Medical Center Lihuili Hospital
    Ningbo, Zhejiang 315040, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jun 2027, 18 months after the start.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 18 months is below that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2025
First posted
Dec 29, 2025
StartActual
Dec 13, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07307235
Collaborators
Sanofi (China) Investment Co., Ltd
Responsible party
Sponsor
First posted
Dec 29, 2025
Start date
Dec 13, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Jul 7, 2026

Study contacts

Xiaoying li, Professor
Contact
li.xiaoying@zs-hospital.sh.cn
+862164041990

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion